Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases.
cutaneous lupus erythematosus
discontinuation
dose tapering
hydroxychloroquine
long-term remission
remission
systemic lupus erythematosus
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
27
10
2021
revised:
22
03
2022
accepted:
28
03
2022
pubmed:
8
4
2022
medline:
22
7
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
Little is known about the prevalence and factors associated with long-term remission in cutaneous lupus erythematosus (CLE). To assess the prevalence, the factors associated with remission, and the long-term remission with and without treatment during CLE. Longitudinal cohort study including biopsy-proven patients with CLE seen between November 1, 2019 and April 30, 2021, with at least 6 months of follow-up after diagnosis. Demographic data, CLE subtypes, remission status, and treatments were recorded. Remission was defined by a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity score of 0. Long-term remission was defined by remission >3 years. Among 141 patients included (81% of women), 93 (66%) were in remission at last follow-up with a median duration since diagnosis of 11.4 years (interquartile range, 4.2-24.7). Long-term remission was observed in 22 (19%) of 114 patients with at least 3 years of follow-up, including 5 (4.4%) with no systemic treatment. Active smoking (odds ratio, 0.22 [95%CI: 0.05-0.97]; P = .04) and discoid CLE lesions (odds ratio, 0.14 [95%CI, 0.04-0.48]; P = .004) were associated with a lower risk of long-term remission. Partial retrospective data collection and tertiary center population. Long-term remission is rare in CLE and negatively associated with active smoking and discoid CLE.
Sections du résumé
BACKGROUND
Little is known about the prevalence and factors associated with long-term remission in cutaneous lupus erythematosus (CLE).
OBJECTIVES
To assess the prevalence, the factors associated with remission, and the long-term remission with and without treatment during CLE.
METHODS
Longitudinal cohort study including biopsy-proven patients with CLE seen between November 1, 2019 and April 30, 2021, with at least 6 months of follow-up after diagnosis. Demographic data, CLE subtypes, remission status, and treatments were recorded. Remission was defined by a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity score of 0. Long-term remission was defined by remission >3 years.
RESULTS
Among 141 patients included (81% of women), 93 (66%) were in remission at last follow-up with a median duration since diagnosis of 11.4 years (interquartile range, 4.2-24.7). Long-term remission was observed in 22 (19%) of 114 patients with at least 3 years of follow-up, including 5 (4.4%) with no systemic treatment. Active smoking (odds ratio, 0.22 [95%CI: 0.05-0.97]; P = .04) and discoid CLE lesions (odds ratio, 0.14 [95%CI, 0.04-0.48]; P = .004) were associated with a lower risk of long-term remission.
LIMITATIONS
Partial retrospective data collection and tertiary center population.
CONCLUSION
Long-term remission is rare in CLE and negatively associated with active smoking and discoid CLE.
Identifiants
pubmed: 35390427
pii: S0190-9622(22)00549-7
doi: 10.1016/j.jaad.2022.03.056
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-332Informations de copyright
Copyright © 2022 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest The authors have no conflicts of interest to disclose.